CN Patent

CN114903902A — GnRH受体拮抗剂联合雄激素受体拮抗剂在制备治疗前列腺癌药物中的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2022-08-16 · 4y expired

What this patent protects

本公开涉及GnRH受体拮抗剂联合雄激素受体拮抗剂在制备治疗前列腺癌药物中的用途。具体而言，本公开涉及的GnRH受体拮抗剂为式(I)所示化合物或其可药用盐。

USPTO Abstract

本公开涉及GnRH受体拮抗剂联合雄激素受体拮抗剂在制备治疗前列腺癌药物中的用途。具体而言，本公开涉及的GnRH受体拮抗剂为式(I)所示化合物或其可药用盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN114903902A
Jurisdiction
CN
Classification
—
Expires
2022-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.